US 11,951,115 B2
Methods of treating retinal vasculopathies
Sharon Klier, South San Francisco, CA (US); and Jamie Dananberg, South San Francisco, CA (US)
Assigned to Unity Biotechnology, Inc., South San Francisco, CA (US)
Filed by Unity Biotechnology, Inc., South San Francisco, CA (US)
Filed on Apr. 12, 2022, as Appl. No. 17/719,066.
Claims priority of provisional application 63/325,056, filed on Mar. 29, 2022.
Claims priority of provisional application 63/309,260, filed on Feb. 11, 2022.
Claims priority of provisional application 63/237,454, filed on Aug. 26, 2021.
Claims priority of provisional application 63/174,188, filed on Apr. 13, 2021.
Prior Publication US 2022/0331345 A1, Oct. 20, 2022
Int. Cl. A61K 31/675 (2006.01); A61K 9/00 (2006.01); A61P 27/02 (2006.01)
CPC A61K 31/675 (2013.01) [A61K 9/0019 (2013.01); A61K 9/0048 (2013.01); A61P 27/02 (2018.01)] 33 Claims
 
1. A method of treating a patient suffering from a retinal vasculopathy comprising administering to the patient a therapeutically effective dose of a meglumine salt of a compound of Formula I (Compound-meglumine):

OG Complex Work Unit Chemistry
(R)-5-(4-chlorophenyl)-1-isopropyl-2-methyl-4-(3-(4-(4-((4-((1-(phenylthio)-4-(4-((phosphonooxy)methyl)piperidin-1-yl)butan-2-yl)amino)-3-((trifluoromethyl)sulfonyl)phenyl)sulfonamido)phenyl)piperazin-1-yl)phenyl)-1H-pyrrole-3-carboxylic acid,
wherein the therapeutically effective dose is up to 10 ug of the Compound-meglumine is administered intravitreally (IVT) per eye.